MorphoSys Confident Of A Win Over AbbVie In Myelofibrosis
Phase III Pelabresib Readout Before Year-End
Sales of the lymphoma drug Monjuvi continue to underwhelm but MorphoSys believes that its investigational BET inhibitor, pelabresib, can become a standard of care for the rare bone marrow disease myelofibrosis.
